BIPOLAR DISORDER EXACTS TWICE DEPRESSION'S TOLL IN WORKPLACE

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



U.S. Department of Health and Human Services 
NATIONAL INSTITUTES OF HEALTH 
NIH News 
National Institute of Mental Health (NIMH)
http://www.nimh.nih.gov/
National Institute on Drug Abuse (NIDA)
http://www.nida.nih.gov/
National Center for Research Resources (NCRR)
http://www.ncrr.nih.gov/ 

EMBARGOED FOR RELEASE: Friday, September 1, 2006; 12:01 a.m. ET 

CONTACT: Jules Asher, NIMH press office (NIMHpress@xxxxxxx),
301-443-4536, 

BIPOLAR DISORDER EXACTS TWICE DEPRESSION'S TOLL IN WORKPLACE
Productivity Lags Even After Mood Lifts

Bipolar disorder costs twice as much in lost productivity as major
depressive disorder, a study funded by the National Institutes of
Health's (NIH) National Institute of Mental Health (NIMH) has found.
Each U.S. worker with bipolar disorder averaged 65.5 lost workdays in a
year, compared to 27.2 for major depression. Even though major
depression is more than six times as prevalent, bipolar disorder costs
the U.S. workplace nearly half as much -- a disproportionately high
$14.1 billion annually. Researchers traced the higher toll mostly to
bipolar disorder's more severe depressive episodes rather than to its
agitated manic periods. The study by Drs. Ronald Kessler, Philip Wang,
Harvard University, and colleagues, is among two on mood disorders in
the workplace published in the September 2006 issue of the "American
Journal of Psychiatry".

Their study is the first to distinguish the impact of depressive
episodes due to bipolar disorder from those due to major depressive
disorder on the workplace. It is based on one-year data from 3378
employed respondents to the National Co-morbidity Survey Replication, a
nationally representative household survey of 9,282 U.S. adults,
conducted in 2001-2003.

The researchers measured the persistence of the disorders by asking
respondents how many days during the past year they experienced an
episode of mood disorder. They judged the severity based on symptoms
during a worst month. Lost work days due to absence or poor functioning
on the job, combined with salary data, yielded an estimate of lost
productivity due to the disorders.

Poor functioning while at work accounted for more lost days than
absenteeism. Although only about 1 percent of workers have bipolar
disorder in a year, compared to 6.4 percent with major depression, the
researchers projected that bipolar disorder accounts for 96.2 million
lost workdays and $14.1 billion in lost salary-equivalent productivity,
compared to 225 million workdays and $36.6 billion for major depression
annually in the United States.

About three-fourths of bipolar respondents had experienced depressive
episodes over the past year, with about 63 percent also having agitated
manic or hypomanic episodes. The bipolar-associated depressive episodes
were much more persistent -- affecting 134-164 days -- compared to only
98 days for major depression. The bipolar-associated depressive episodes
were also more severe. All measures of lost work performance were
consistently higher among workers with bipolar disorder who had major
depressive episodes than those who reported only manic or hypomanic
episodes. The latter workers' lost performance was on a par with workers
who had major depressive disorder.

"Major depressive episodes due to bipolar disorder are sometimes
incorrectly treated as major depressive disorder," noted Wang. "Since
antidepressants can trigger the onset of mania, workplace programs
should first rule out the possibility that a depressive episode may be
due to bipolar disorder."

Future effectiveness trials could gauge the return on investment for
employers offering coordinated evaluations and treatment for both mood
disorders, he said.

Also participating in the study were: Dr. Kathleen Merikangas, NIMH; Dr.
Minnie Ames and Robert Jin, Harvard University; Dr. Howard Birnbaum,
Paul Greenberg, Analysis Group Inc.; Dr. Robert Hirschfeld, University
of Texas; Dr. Hagop Akiskal, University of California San Diego.

The National Institute on Drug Abuse (NIDA), Substance Abuse and Mental
Health Services Administration (SAMHSA), Robert Wood Johnson Foundation
and John W. Alden Trust provided supplemental funding.

In a related NIMH-funded study in the same issue of the "American
Journal of Psychiatry", Drs. Debra Lerner, David Adler, and colleagues,
Tufts University School of Medicine and Tufts-New England Medical
Center, found that many aspects of job performance are impaired by
depression and that the effects linger even after symptoms have
improved.

The researchers tracked the job performance and productivity of 286
employed patients with depression and dysthymia, 93 with rheumatoid
arthritis and 193 healthy controls recruited from primary care physician
practices for 18 months. While job performance improved as depression
symptoms waned, even "clinically improved" depressed patients performed
worse than healthy controls on mental, interpersonal, time management,
output and physical tasks. The arthritis patients showed greater
impairment, compared to healthy controls, only for physical job demands.

Noting that 44 percent of the depressed patients were already taking
antidepressants when they began the study and still met clinical
criteria for depression -- and that job performance continued to suffer
despite some clinical improvement -- the researchers recommended that
the goal of depression treatment should be remission. They also suggest
that health professionals pay more attention to recovery of work
function and that workplace supports be developed, perhaps through
employee assistance programs and worksite occupational health clinics,
to help depressed patients better manage job demands.

Also participating in the study were: Dr. William Rogers, Dr. Hong
Chang, Leueen Lapitsky, Tufts-New England Medical Center; Dr. Thomas
McLaughlin, University of Massachusetts Medical School.

The Tufts-New England Medical Center General Clinical Research Center is
funded by the NIH's National Center for Research Resources.

The National Institute of Mental Health (NIMH) mission is to reduce the
burden of mental and behavioral disorders through research on mind,
brain, and behavior. More information is available at the NIMH website,
http://www.nimh.nih.gov.

The National Institute on Drug Abuse is a component of the National
Institutes of Health, U.S. Department of Health and Human Services. NIDA
supports more than 85 percent of the world's research on the health
aspects of drug abuse and addiction. The Institute carries out a large
variety of programs to ensure the rapid dissemination of research
information and its implementation in policy and practice. Fact sheets
on the health effects of drugs of abuse and information on NIDA research
and other activities can be found on the NIDA home page at
http://www.drugabuse.gov.

NCRR provides laboratory scientists and clinical researchers with the
environments and tools they need to understand, detect, treat, and
prevent a wide range of diseases. With this support, scientists make
biomedical discoveries, translate these findings to animal-based
studies, and then apply them to patient-oriented research. Ultimately,
these advances result in cures and treatments for both common and rare
diseases. NCRR also connects researchers with one another, and with
patients and communities across the nation. These connections bring
together innovative research teams and the power of shared resources,
multiplying the opportunities to improve human health. For more
information, visit www.ncrr.nih.gov. 

The National Institutes of Health (NIH) -- "The Nation's Medical
Research Agency" -- includes 27 Institutes and Centers and is a
component of the U.S. Department of Health and Human Services. It is the
primary federal agency for conducting and supporting basic, clinical and
translational medical research, and it investigates the causes,
treatments, and cures for both common and rare diseases. For more
information about NIH and its programs, visit www.nih.gov.
  
##
 
This NIH News Release is available online at:
http://www.nih.gov/news/pr/sep2006/nimh-01.htm.

To subscribe (or unsubscribe) from this list, go to
http://list.nih.gov/cgi-bin/wa?SUBED1=nihpress&A=1.

[Index of Archives]     [CDC News]     [FDA News]     [USDA News]     [Yosemite News]     [Steve's Art]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux